Welcome to Molecular Neurobiology, the premier journal dedicated to the exploration of the molecular mechanisms underlying nervous system function and pathophysiology. Published by Springer, this journal provides an essential platform for disseminating high-quality research in the rapidly evolving fields of Cellular and Molecular Neuroscience and Neurology, boasting an impressive impact factor that reflects its esteemed position within the academic community. With its ranking in the Q1 and Q2 quartiles for various neuroscience categories, Molecular Neurobiology stands at the forefront of groundbreaking discoveries, showcasing innovative studies that bridge basic science and clinical application. Researchers and professionals are invited to contribute to its rich portfolio, which spans from fundamental insights into cellular processes to advanced therapeutic strategies. Although Molecular Neurobiology does not operate as an Open Access journal, its influential body of work remains accessible through institutional and personal subscriptions. As we converge from 1987 to 2024, we continue to aim for excellence, seeking to catalyze progress in understanding neurological diseases and enhance the scientific dialogue within the neuroscience community.

NEUROBIOLOGY OF DISEASE is a premier journal dedicated to advancing the understanding of neurological disorders and the underlying biological processes, published by Academic Press Inc, Elsevier Science. With an impressive impact factor indicative of its significance—ranked in the Q1 quartile in Neurology for 2023 and occupying the 14th rank out of 192 journals in the field of Neuroscience and Neurology—this journal serves as a critical resource for researchers, clinicians, and students alike. The journal has a rich history since its inception in 1994, continuously evolving its scope to encompass groundbreaking research and insights into neurobiological mechanisms and disease pathology. Though it currently does not provide Open Access options, NEUROBIOLOGY OF DISEASE remains a vital vessel for disseminating knowledge that significantly contributes to the field of neurology, fostering an understanding that can lead to innovative therapeutic strategies.

Current Alzheimer Research is a pivotal journal dedicated to advancing knowledge in the field of neurology, with a particular focus on Alzheimer's disease and related neurodegenerative disorders. Published by BENTHAM SCIENCE PUBL LTD, this journal contributes to the growing body of literature aimed at bridging the gap between clinical research and practical application. Operating out of the United Arab Emirates, it has established itself as a reputable source for interdisciplinary research and clinical studies, reflecting its category quartiles ranking of Q3 in both Neurology and Clinical Neurology as of 2023. The journal, which spans from 2004 to 2024, provides scientists, clinicians, and students with up-to-date research findings while fostering an environment of knowledge exchange. Researchers are encouraged to submit their work, share insights, and engage with the latest discoveries that aim to enhance understanding and treatment strategies in Alzheimer’s disease, thereby addressing one of the most pressing challenges in neuroscience today.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

NEUROBIOLOGY OF AGING, published by Elsevier Science Inc, is a premier journal dedicated to advancing our understanding of the complex interactions between the aging process and neurobiological mechanisms. With an ISSN of 0197-4580 and E-ISSN 1558-1497, the journal has established itself as a critical resource in the fields of Aging, Developmental Biology, Geriatrics and Gerontology, Clinical Neurology, and Neuroscience. Boasting a Q1 ranking in multiple categories, the journal is positioned within the top echelons of scholarly publication, underscoring its significant impact with an impressive Scopus ranking in various subfields. Committed to disseminating high-quality, peer-reviewed research, NEUROBIOLOGY OF AGING welcomes original articles, reviews, and research notes aiming to uncover the underlying processes of aging on the nervous system, fostering collaboration among researchers, professionals, and students alike. Although primarily subscription-based, the journal continues to play a vital role in shaping the discourse on aging and neurobiology, making it an essential publication for those engaged in this dynamic field.

Neurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.

Frontiers in Aging Neuroscience, published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to the field of aging neuroscience, with its ISSN being 1663-4365. Since its inception in 2009, this journal has provided a platform for researchers to disseminate their findings on the neurological aspects of aging, addressing critical issues that impact cognition and overall brain health in the elderly population. With a commendable 2023 impact factor, the journal ranks in the Q2 category in both Aging and Cognitive Neuroscience, positioning it among the top-tier publications in these fields. Notably, it is recognized within Scopus, ranking #32 out of 115 in Neuroscience (Cognitive Neuroscience) and #20 out of 38 in the Aging sector, with corresponding percentiles of 72nd and 48th, respectively. As an open-access journal, it promotes unrestricted access to research findings, fostering collaboration and innovation among the academic community. Researchers, professionals, and students alike can explore cutting-edge studies that contribute to understanding the complexities of neurological aging and work towards improving cognitive health in an aging society.

Journal of Alzheimer's Disease Reports, published by IOS PRESS, is an essential open-access platform dedicated to advancing research in the fields of clinical psychology, geriatrics, gerontology, neuroscience, and psychiatry. Since its inception in 2017, this journal has rapidly gained recognition, achieving a commendable status reflected in its 2023 category quartiles, notably ranking Q2 in Clinical Psychology and Psychiatry and Mental Health. With a sustained commitment to disseminating high-quality research and facilitating collaboration among scientists, the journal offers insights into the critical aspects of Alzheimer's disease and related cognitive disorders. Given its positions in the Scopus ranks, it serves as a crucial resource for academics and practitioners alike, empowering them to contribute effectively to the ongoing discourse in cognitive health. The journal embraces open access, ensuring that all research findings are freely available to the global community, thereby enhancing visibility and engagement. With a focus on fostering innovation and knowledge transfer, Journal of Alzheimer's Disease Reports is poised to make an enduring impact in the field of dementia research.

Journal of Alzheimer's Disease, published by IOS Press, stands as a pivotal resource in the fight against Alzheimer's and related neurodegenerative disorders. With an ISSN of 1387-2877 and an E-ISSN of 1875-8908, this esteemed journal has evolved since its inception in 1998, providing a vital platform for academic research and clinical practice in the realms of Clinical Psychology, Geriatrics and Gerontology, Neuroscience, and Psychiatry and Mental Health. Ranked in the Q1 category across several disciplines, including Clinical Psychology and Geriatrics, this journal not only highlights significant advancements in understanding Alzheimer's disease but also fosters interdisciplinary dialogue among researchers, healthcare professionals, and policymakers. Boasting robust Scopus rankings—such as 49th in Clinical Psychology and 29th in Geriatrics—this journal is committed to disseminating high-quality research that informs both therapeutic strategies and public health initiatives. The Journal of Alzheimer's Disease is an essential resource for anyone dedicated to exploring the complexities of cognitive decline and enhancing care for affected individuals.

npj Aging and Mechanisms of Disease is a leading open-access journal dedicated to advancing the understanding of the biological mechanisms underlying aging and age-related diseases. Published by NATURE PORTFOLIO in the United Kingdom, this journal has established itself as a vital resource within the fields of Aging and Geriatrics and Gerontology, proudly holding a prestigious Q1 ranking in both categories as of 2023. With an impressive Scopus ranking, placing it in the top 10 for Geriatrics and Gerontology, and the top 9 for Aging, the journal is committed to disseminating high-quality, peer-reviewed research that offers innovative insights and fosters collaboration among researchers and practitioners. Since its inception in 2015, npj Aging and Mechanisms of Disease has embraced the open-access model, ensuring that groundbreaking findings are freely available to all, thereby promoting widespread knowledge-sharing within the scientific community. This journal serves as an essential platform for those seeking to explore the complex interplay of genetic, molecular, and environmental factors that influence aging and its associated challenges.